Michigan Alzheimer's Disease Research Center

密歇根阿尔茨海默病研究中心

基本信息

批准号：
10261108
负责人：
Henry L Paulson
金额：
$ 309.72万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-01 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10261108
关键词：
Address Affect African American Aging Alzheimer&apos s Disease Alzheimer&apos s disease related dementia Alzheimer&apos s disease therapy American Amyloid beta-Protein Award Biological Markers Capsicum Centers of Research Excellence Clinical Cognition Collaborations Communities Dementia Development Diagnosis Diagnostic Disclosure Disease Education and Outreach Elderly Ensure Environment Foundations Funding Health Health Professional Heterogeneity Hispanics Knowledge Latino Lead Lewy Body Dementia Light Link Longitudinal cohort Mentors Michigan Modification Molecular Profiling Multi-Institutional Clinical Trial Nerve Degeneration Nonpharmacologic Therapy Parkinson Disease Participant Peripheral Population Research Protein-Folding Disease Research Research Subjects Research Support Resources Risk Scientist Site Students Therapeutic Training United States Universities Vascular Dementia Work aging demography brain dysfunction contextual factors disorder risk education research experience frontotemporal lobar dementia-amyotrophic lateral sclerosis gene environment interaction health disparity improved innovation molecular imaging neuroimaging marker next generation novel novel diagnostics novel marker novel therapeutic intervention outreach programs racial diversity recruit symposium training opportunity translational neuroscience

项目摘要

ABSTRACT – OVERALL Four years ago the Michigan ADRC (MADRC) was established as a new consortium linking the three major research universities in Michigan: University of Michigan, Michigan State University, and Wayne State University. Serving the entire state of Michigan, the new MADRC achieved its milestones in wide-ranging activities and research that emphasized a central theme: to identify, understand and treat the myriad non-β- amyloid contributions to brain dysfunction and degeneration in Alzheimer’s disease and related dementias (ADRD). With continued NIA support, the MADRC proposes to maintain this central theme because it captures the diverse expertise of our dementia scientists, sheds light on ADRD heterogeneity, and reflects the experience of the racially diverse pool of research participants engaged in MADRC-sponsored studies. To achieve its objectives, the MADRC has four major aims: 1) Catalyze and perform research of the highest impact in ADRD; 2) Promote regional efforts to understand, diagnose and treat the full spectrum of dementias through collaborative scientific and outreach efforts; 3) Provide training and research opportunities for health care professionals, scientists, and students in ADRD through innovative educational and mentoring programs; and 4) Collaborate with other ADRCs, the NACC, NCRAD, and other multi-center efforts to lead the field in developing new diagnostic and therapeutic interventions for these devastating diseases. The integrated efforts of seven Cores, including new Neuroimaging and Biomarker cores, will support a wide range of basic, clinical, translational and health disparities research advancing the field toward: improved understanding of disease mechanisms; more precise disease identification across the dementia spectrum; development of novel biomarkers; increased knowledge of the basis for health disparities that disproportionately affect Black Americans; development of non-pharmacological therapies; and the identification and modification of disease risks. The Research Education Component (REC) will serve as the centerpiece of innovative training opportunities spanning all the Cores, and a new Leaders Initiative will support and promote a diverse group of next-generation leaders in dementia research. Benefitting from the outstanding resources of all three universities and strong multi-institutional support, the MADRC is poised to make new discoveries, educate the public, and train next-generation leaders as we seek to achieve the milestones set forth in the National Alzheimer’s Project Act.

摘要 – 总体四年前，密歇根州 ADRC (MADRC) 成立，作为一个连接三大主要机构的新联盟密歇根州的研究型大学：密歇根大学、密歇根州立大学和韦恩州立大学新的 MADRC 为整个密歇根州服务，在广泛的领域取得了里程碑式的成就。强调中心主题的活动和研究：识别、理解和治疗无数的非β- 淀粉样蛋白对阿尔茨海默病和相关痴呆症的脑功能障碍和退化的影响 (ADRD) 在 NIA 的持续支持下，MADRC 提议维持这一中心主题，因为它抓住了这一点。我们痴呆症科学家的多样化专业知识揭示了 ADRD 异质性，并反映了参与 MADRC 资助的研究的不同种族研究参与者的经验。为了实现其目标，MADRC 有四个主要目标： 1) 促进和开展最高水平的研究 ADRD 的影响；2) 促进区域努力了解、诊断和治疗各种痴呆症通过合作科学和推广工作；3) 提供健康培训和研究机会；通过创新的教育和指导计划，护理 ADRD 中的专业人员、科学家和学生； 4) 与其他 ADRC、NACC、NCRAD 和其他多中心机构合作，在该领域处于领先地位针对这些破坏性疾病开发新的诊断和治疗干预措施。七个核心，包括新的神经影像和生物标记核心，将支持广泛的基础、临床、转化和健康差异研究推动该领域的发展：增进对疾病的了解机制；更精确地识别整个痴呆症谱系；开发新的药物；生物标志物；增加对对黑人影响不成比例的健康差异基础的了解美国人；非药物疗法的开发；以及疾病的识别和治疗；研究教育部分（REC）将作为创新培训的核心。涵盖所有核心的机会，新的领导者计划将支持和促进多元化的群体痴呆症研究的下一代领导者受益于这三位的杰出资源。大学和强大的多机构支持，MADRC 准备做出新发现，教育公众，并培训下一代领导人，因为我们寻求实现国家战略中规定的里程碑阿尔茨海默氏症项目法案。